Expert Interviews

Sean M. Oser, MD, MPH, provides an in-depth look at the use of analytics in diabetes management.

Sean M. Oser, MD, MPH, opens a discussion surrounding key considerations in diabetes management.

Arwen Podesta, MD, details the therapeutic areas in which prescription digital therapeutics (PDTs) have been studied and show the most promise, as well as some of the unmet needs in patients with mental health conditions that PDTs may be able to address.

Arwen Podesta, MD, defines what prescription digital therapeutics (PDTs) are, describes how they differ from nonprescription digital health tools, and details the FDA review process for PDTs.

An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.

Jill Zouzoulas, M.D., FACR, describes the best practices for incorporating patient perspectives when determining the ideal route of administration for those with rheumatologic diseases.

Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, shares expert perspectives on the important role of risk stratification in determining optimal treatment decisions for patients with low-risk or high-risk myelofibrosis.

An expert on myelofibrosis provides clinical insights on features of the disease that can impact patient quality of life, including splenomegaly, hypertension, and bone pain.

An expert rheumatologist highlights the billing process for patients receiving biologic therapies, as well as a study that highlights patient reported outcomes in patients with inflammatory arthritis utilizing intravenous biologics.

Dr. Zouzoulas discusses key patient considerations to consider when deciding on an intravenous or subcutaneous biologic.

An expert pulmonologist discusses the best ways to manage acute exacerbations and the psychosocial component of idiopathic and progressive pulmonary fibrosis.

Dr. Paul Frohna discusses the importance of non-pharmacological modalities, as well as utilizing multidisciplinary care, for patients with idiopathic and progressive pulmonary fibrosis.

A clinical pharmacy manager discusses challenges frequently encountered in the treatment of patients with myelofibrosis.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, provides an overview of myelofibrosis, covering its incidence and prevalence in the United States as well as patient presentation and prognosis.

Paul Noble, MD, discusses the importance of early diagnosis in patients with IPF or PPF.

A medical expert shares critical insights around biologic utilization.

Paul Noble, MD, discusses epidemiology facts, differential diagnosis, and arriving at a IPF or PPF diagnosis.

Jill Zouzoulas, MD, FACR, opens a discussion highlighting use of biologics in her practice.

Paul Noble, MD, analyzes variables contributing to IPF or PPF disease prognosis.

Paul Noble, MD, opens a discussion surrounding the current treatment landscape and key elements to address in the management of idiopathic pulmonary fibrosis.

Lawrence Eichenfield, MD, discusses promising avenues for future research and innovation in the field of atopic dermatitis.

A diabetes expert investigates the personal factors impacting patients' adoption of diabetes devices and technologies, while concurrently exploring specific plan policies, wellness initiatives, and benefit designs that could most effectively and equitably enhance diabetes outcomes across diverse demographic groups.

Focusing on the future treatment landscape of atopic dermatitis, Dr Eichenfield discusses current unmet needs and highlights standout studies and presentations from the 2024 AAD Annual Meeting.

Lawrence Eichenfield, MD, provides clinical insights on evaluating patient response to therapy and managing adverse effects.

A diabetes expert examines how digital devices, virtual care access, and medication therapies can enhance convenience, outcomes, and cost-effectiveness in diabetes management, spotlighting the transformative potential of continuous glucose monitors to empower patients and elevate the quality of patient care.

David Hines underscores the criticality of routine monitoring for members with diabetes, encompassing glycemic control, blood pressure, and cholesterol levels, while simultaneously highlighting the indispensable nature of patient buy-in, engagement in daily self-management routines, and access to educational resources to bridge prevalent knowledge deficits, all geared towards optimizing diabetes care.

An expert on the treatment of atopic dermatitis provides insights on navigating insurance barriers and discusses how managed care organizations can incentivize and support the implementation of evidence-based guidelines and best practices across healthcare settings.

An expert dermatologist outlines factors that influence treatment selection for patients with atopic dermatitis and discusses how often patients need systemic therapy, given the available topical therapy options.

Veteran healthcare lobbyist discussed the prospects for the Senate passing comprehensive PBM legislation in the most recent episode of Managed Healthcare's DC Roundtable podcast.